Label-free LC-MSe in tissue and serum reveals protein networks underlying differences between benign and malignant serous ovarian tumors.
about
Proteomics of ovarian cancer: functional insights and clinical applicationsSystems medicine: evolution of systems biology from bench to bedsideAssociation of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation.Understanding Ovarian Cancer: iTRAQ-Based Proteomics for Biomarker Discovery
P2860
Label-free LC-MSe in tissue and serum reveals protein networks underlying differences between benign and malignant serous ovarian tumors.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Label-free LC-MSe in tissue an ...... lignant serous ovarian tumors.
@ast
Label-free LC-MSe in tissue an ...... lignant serous ovarian tumors.
@en
Label-free LC-MSe in tissue an ...... lignant serous ovarian tumors.
@nl
type
label
Label-free LC-MSe in tissue an ...... lignant serous ovarian tumors.
@ast
Label-free LC-MSe in tissue an ...... lignant serous ovarian tumors.
@en
Label-free LC-MSe in tissue an ...... lignant serous ovarian tumors.
@nl
prefLabel
Label-free LC-MSe in tissue an ...... lignant serous ovarian tumors.
@ast
Label-free LC-MSe in tissue an ...... lignant serous ovarian tumors.
@en
Label-free LC-MSe in tissue an ...... lignant serous ovarian tumors.
@nl
P2093
P2860
P50
P1433
P1476
Label-free LC-MSe in tissue an ...... alignant serous ovarian tumors
@en
P2093
Carmen A Argmann
Danielle Meijer
Gemma G Kenter
Johannes P Vissers
Marrije R Buist
Wouter Wegdam
P2860
P304
P356
10.1371/JOURNAL.PONE.0108046
P407
P577
2014-09-29T00:00:00Z